Brought to you by 
Arris and Bayer sign $70mm R&D deal for inflammatory drugs
10 Oct 2002
Executive Summary
Arris signed a five-year agreement with Bayer to develop drugs and diagnostics from Arris' inflammation program, including inhibitors of tryptase and chymase. The deal is potentially worth $70 million in funding to Arris.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arris and Bayer sign $70mm R&D deal for inflammatory drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice